Palvella Therapeutics PVLA Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Palvella Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's cash ratio?
- Palvella Therapeutics (PVLA) reported cash ratio of 22.6× in Q1 2026.
- How has Palvella Therapeutics's cash ratio changed year-over-year?
- Palvella Therapeutics's cash ratio increased by 169.0% year-over-year, from 8.4× to 22.6×.
- What is the long-term trend for Palvella Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), Palvella Therapeutics's cash ratio has grown at a 10.0% compound annual growth rate (CAGR), from 3.2× to 5.1×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.